BR0313209A - proteìnas que interagem com mk2 - Google Patents

proteìnas que interagem com mk2

Info

Publication number
BR0313209A
BR0313209A BRPI0313209-9A BR0313209A BR0313209A BR 0313209 A BR0313209 A BR 0313209A BR 0313209 A BR0313209 A BR 0313209A BR 0313209 A BR0313209 A BR 0313209A
Authority
BR
Brazil
Prior art keywords
proteins
interact
inflammation
relates
bind
Prior art date
Application number
BRPI0313209-9A
Other languages
English (en)
Inventor
Lih-Ling Lin
Yvonne M Yannoni
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0313209A publication Critical patent/BR0313209A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

"PROTE NAS QUE INTERAGEM COM MK2" A presente invenção refere-se usos de proteínas que se ligam a MK2 ara modular inflamação. Mais particulamente, a invenção refere-se a usos de proteínas que se ligam a MK2 para tratar condições que estejam relacionadas à inflamação. A invenção é útil para tratamento de condições inflamatórias, particulamente aquelas em que uma diminuição na inflamação seria terapeuicamente vantajosa.
BRPI0313209-9A 2002-08-02 2003-08-01 proteìnas que interagem com mk2 BR0313209A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40004402P 2002-08-02 2002-08-02
PCT/US2003/023981 WO2004012660A2 (en) 2002-08-02 2003-08-01 Mk2 interacting proteins

Publications (1)

Publication Number Publication Date
BR0313209A true BR0313209A (pt) 2007-07-24

Family

ID=31495774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313209-9A BR0313209A (pt) 2002-08-02 2003-08-01 proteìnas que interagem com mk2

Country Status (10)

Country Link
US (1) US7364870B2 (pt)
EP (1) EP1572092A4 (pt)
JP (1) JP2006515159A (pt)
CN (1) CN1735687A (pt)
AU (1) AU2003257962A1 (pt)
BR (1) BR0313209A (pt)
CA (1) CA2494577A1 (pt)
IL (1) IL166610A0 (pt)
MX (1) MXPA05001364A (pt)
WO (1) WO2004012660A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155228T3 (da) 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
CA2857625A1 (en) * 2011-12-05 2013-06-13 Medical & Biological Laboratories Co., Ltd. Method for detecting protein-protein interaction
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
JP5904638B2 (ja) * 2012-04-11 2016-04-13 株式会社日本マイクロニクス 多層配線基板とその製造方法
US11726081B2 (en) 2019-02-15 2023-08-15 Regents Of The University Of Minnesota Methods to identify modulators of tau protein structure
US11656221B2 (en) * 2019-06-11 2023-05-23 Regents Of The University Of Minnesota Methods to identify modulators of actin-binding proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
US5624899A (en) 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma

Also Published As

Publication number Publication date
WO2004012660A2 (en) 2004-02-12
CN1735687A (zh) 2006-02-15
EP1572092A4 (en) 2007-09-05
CA2494577A1 (en) 2004-02-12
IL166610A0 (en) 2006-01-15
MXPA05001364A (es) 2005-08-03
JP2006515159A (ja) 2006-05-25
EP1572092A2 (en) 2005-09-14
AU2003257962A1 (en) 2004-02-23
US7364870B2 (en) 2008-04-29
WO2004012660A3 (en) 2005-10-20
US20060094101A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
BRPI0316438B8 (pt) uso de eritropoietina em doenças cardíacas
PT1049767E (pt) Coelho transgenico que expressa uma lipoproteina (a) humana funcional
BRPI0613358A8 (pt) ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
UY26058A1 (es) Compuestos utiles como antiinflamatorios ley 17.164 art. 127
BR112015027319A2 (pt) métodos e composições para modular a expressão de apolipoproteína (a)
BR0015026A (pt) Indóis substituìdos para a modulação da atividade de nfkb
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
CR10513A (es) Proteinas de enlace multivalente de una sola cadena con funcion de ejecutador
BR0207285A (pt) Agonistas de ppar
BRPI0509150B8 (pt) compostos para a inibição de angiogênese e uso destes
TWI256387B (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
BR9913855A (pt) 1-2-3-4- tetrahidroquinolinas substituìdas na posição 2 e substituìdas na posição 4 com amino como inibidores de cetp
BR0313209A (pt) proteìnas que interagem com mk2
BRPI0410876B8 (pt) composição, proteína de fusão, molécula de cdna, vetor, célula hospedeira procariótica recombinante, método para preparar uma molécula inibidora do complemento, e, usos de uma composição e de uma proteína de fusão
BR0113661A (pt) Composições farmacêuticas para a liberação tópica de inibidores da enzima ciclooxigenase-2
YU40502A (sh) 4-piridinil-n-acil-l-fenilalanini
CR9528A (es) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
BR9810121A (pt) Utilização do acido petroselìnico nativo ou esterificado
BRPI0416544A (pt) proteìna de ligação de gag
BR112012004697A2 (pt) purificação melhorada de proteína através de uma eluição da proteína a modificada.
HK1041476A1 (en) Cell adhesion-inhibiting antiinflammatory and immunesuppressive compounds
PT1150991E (pt) Composicoes para o tratamento da resposta inflamatoria
BR0014860A (pt) Métodos para a produção de uma molécula alvo em um animal transgênico e purificação da molécula alvo
BR9904054A (pt) Proteìnas que se ligam a diarilsulfoniluréia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8AANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.